Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Friday, January 28, 2022
The bispecific antibody talquetamab in combination with the monoclonal antibody daratumumab was well tolerated in patients with multiple myeloma, according to Ajai Chari, MD, of Mount Sinai School of Medicine, New York, and colleagues. The researchers found that the combination treatment resulted in proinflammatory cytokine production and T-cell activation. These phase Ib study findings, which were presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 161), support further clinical development of this combination regimen.
The study included patients diagnosed with multiple myeloma who have received three or more prior lines of therapy (including a proteasome inhibitor and an immunomodulatory drug) or were double refractory to a proteasome inhibitor and an immunomodulatory drug. Patients were administered subcutaneous talquetamab and daratumumab in 28-day cycles in different dosing cohorts (with step-up dosing for talquetamab). The study aimed to identify the recommended phase II dose of talquetamab and daratumumab and to characterize the therapy’s level of safety.
The 23 patients treated with subcutaneous talquetamab and daratumumab were separated into different cohorts: daratumumab at 1,800 mg plus talquetamab at 400 µg/kg weekly (n = 8), talquetamab at 400 µg/kg biweekly (n = 5), and talquetamab at 800 µg/kg biweekly (n = 10). Participants had received a median of six prior lines of therapy; 82.6% were triple-class–exposed (82.6% received prior daratumumab and 8.7% received prior isatuximab), and 73.9% were penta-drug–exposed.
The median time to first response across talquetamab-plus-daratumumab cohorts was 1 month. Adverse events were reported in 95.7% of patients. Grade 3 or 4 adverse events were reported in 78% of patients. The most frequently reported grade 3 or 4 adverse events were neutropenia (39.1%), thrombocytopenia (39.1), and anemia (34.8).
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
2021 ASH Annual Meeting & Exposition
